2026 Annual Meeting | C67 - The Essentials of Demyelinating Neuropathies: What Every Neurologist Should Know

Date Sunday 04/19/26

Time 01:00 PM - 03:00 PM CDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Chafic Y. Karam, MD

Topic(s) Neuromuscular and Clinical Neurophysiology (EMG)

Learning Objectives Participants will learn how to recognize, diagnose, and manage both immune-mediated (e.g. GBS and CIDP) and hereditary demyelinating neuropathies (e.g. CMT). The course emphasizes clinical patterns, diagnostic testing, and treatment principles through illustrative cases, helping participants build confidence in evaluating patients with suspected demyelinating neuropathy.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement, Quality Improvement

Program Level Introductory

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student

Teaching Styles Case-based, Didactic, Audience Participation

Event Timeline
01:00 PM - 01:10 PM CDT	Introduction	Introduction – Overview of demyelinating neuropathies and diagnostic framework. Chafic Y. Karam, MD
01:10 PM - 01:30 PM CDT	Speaker	Guillain-Barré Syndrome – Early recognition, diagnostic challenges, and treatment timing.
01:30 PM - 02:00 PM CDT	Speaker	Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) – Classic and atypical presentations, diagnostic criteria, and evidence-based management. Chafic Y. Karam, MD
02:00 PM - 02:30 PM CDT	Speaker	Hereditary Demyelinating Neuropathies, diagnosis and future therapies.
02:30 PM - 02:50 PM CDT	Speaker	Treatment Updates – Comparative review of immunotherapies, including IVIG, SCIG, and emerging agents such as FcRn inhibitors and complement blockers.
02:50 PM - 03:00 PM CDT	Q&A	Discussion and Q&A Chafic Y. Karam, MD

Faculty Disclosures
Chafic Y. Karam, MD	Dr. Karam has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Alnylam. Dr. Karam has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi. Dr. Karam has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Argenx. Dr. Karam has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Annexon. Dr. Karam has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Nuvig. Dr. Karam has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Applied therapeutics. Dr. Karam has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Karam has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Astra Zeneca. Dr. Karam has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Intellia. Dr. Karam has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Takeda. Dr. Karam has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Vertex.
Paul T. McIntosh, MD	No disclosure on file

��ɫ��

��ɫ��